TRPV1 in migraine pathophysiology

Trends in Molecular Medicine

Volumn 16, Issue 4, 2010, Pages 153-159

  Meents, Jannis E ^a   Neeb, Lars ^a   Reuter, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; CIS CAPSAICIN; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; NERVE GROWTH FACTOR; OLCEGEPANT; SUBSTANCE P; SUMATRIPTAN; TELCAGEPANT; TRIPTAN DERIVATIVE; VANILLOID RECEPTOR 1; ZOLMITRIPTAN;

ALLODYNIA; ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDUCED HEADACHE; EDEMA; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; LACRIMATION; MIGRAINE; NERVE CELL; NONHUMAN; NOSE DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SENSITIZATION; SIDE EFFECT; SPREADING CORTICAL DEPRESSION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CAPSAICIN; FEMALE; HUMANS; HYPERALGESIA; MALE; MICE; MIGRAINE DISORDERS; NOCICEPTORS; RATS; TRIGEMINAL GANGLION; TRPV CATION CHANNELS; UNITED STATES;

EID: 77950519679     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.02.004     Document Type: Article

References (108)

1. Lipton R.B., et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41 (2001) 638-645
2. Stewart W.F., et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia 28 (2008) 1170-1178
3. Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 Suppl 1, 9-160
4. Lipton R.B., et al. Cutaneous allodynia in the migraine population. Ann. Neurol. 63 (2008) 148-158
5. Mayberg M., et al. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 213 (1981) 228-230
6. Edvinsson L. Sensory nerves in man and their role in primary headaches. Cephalalgia 21 (2001) 761-764
7. Buzzi M.G., et al. Neurogenic model of migraine. Cephalalgia 15 (1995) 277-280
8. May A., and Goadsby P.J. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J. Cereb. Blood Flow Metab. 19 (1999) 115-127
9. Caterina M.J., and Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 24 (2001) 487-517
10. Szolcsanyi J. A pharmacological approach to elucidation of the role of different nerve fibres and receptor endings in mediation of pain. J. Physiol. (Paris) 73 (1977) 251-259
11. Nagy J.I., et al. Dose-dependent effects of capsaicin on primary sensory neurons in the neonatal rat. J. Neurosci. 3 (1983) 399-406
12. Szallasi A., et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6 (2007) 357-372
13. Caterina M.J., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
14. Guo A., et al. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur. J. Neurosci. 11 (1999) 946-958
15. Bae Y.C., et al. Expression of vanilloid receptor TRPV1 in the rat trigeminal sensory nuclei. J. Comp. Neurol. 478 (2004) 62-71
16. Cortright D.N., et al. The tissue distribution and functional characterization of human VR1. Biochem. Biophys. Res. Commun. 281 (2001) 1183-1189
17. Westaway S.M. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J. Med. Chem. 50 (2007) 2589-2596
18. Goadsby P.J., et al. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23 (1988) 193-196
19. Williamson D.J., and Hargreaves R.J. Neurogenic inflammation in the context of migraine. Microsc. Res. Tech. 53 (2001) 167-178
20. Goldstein D.J., et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17 (1997) 785-790
21. Diener H.C. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23 (2003) 183-185
22. Lassen L.H., et al. CGRP may play a causative role in migraine. Cephalalgia 22 (2002) 54-61
23. Olesen J., et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350 (2004) 1104-1110
24. Ho T.W., et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372 (2008) 2115-2123
25. Nicoletti P., et al. Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 28 (2008) 9-17
26. Akerman S., et al. Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br. J. Pharmacol. 140 (2003) 718-724
27. Price T.J., et al. Treatment of trigeminal ganglion neurons in vitro with NGF, GDNF or BDNF: effects on neuronal survival, neurochemical properties and TRPV1-mediated neuropeptide secretion. BMC. Neurosci. 6 (2005) 4
28. Akerman S., et al. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br. J. Pharmacol. 142 (2004) 1354-1360
29. Eltorp C.T., et al. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia 20 (2000) 838-844
30. Price T.J., and Flores C.M. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. J. Pain 8 (2007) 263-272
31. Shimizu T., et al. Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat. Brain Res. 1173 (2007) 84-91
32. Hou M., et al. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci. Lett. 330 (2002) 223-226
33. Fusco B.M., et al. Repeated intranasal capsaicin applications to treat chronic migraine. Br. J. Anaesth. 90 (2003) 812
34. Bolay H., et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8 (2002) 136-142
35. Reuter U., et al. Perivascular nerves contribute to cortical spreading depression-associated hyperemia in rats. Am. J. Physiol. 274 (1998) H1979-H1987
36. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 117 Pt 1 (1994) 199-210
37. Tominaga M., et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21 (1998) 531-543
38. Jordt S.E., et al. Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8134-8139
39. Markowitz S., and Moskowitz M.A. Vascular head pain: a neurobiologist's approach. Funct. Neurol. 1 (1986) 351-356
40. Markowitz S., et al. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J. Neurosci. 7 (1987) 4129-4136
41. Phebus, L.A. and Johnson, K.W. (2001) Dural inflammation model of migraine pain. Curr. Protoc. Neurosci. Chapter 9, Unit9
42. Levy D., et al. Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 46 Suppl 1 (2006) S13-S18
43. Dimitriadou V., et al. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 44 (1991) 97-112
44. Zhang X.C., et al. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J. Pharmacol. Exp. Ther. 322 (2007) 806-812
45. Patwardhan A.M., et al. Trigeminal nociceptors express prostaglandin receptors. J. Dent. Res. 87 (2008) 262-266
46. Simonetti M., et al. Comparison of P2X and TRPV1 receptors in ganglia or primary culture of trigeminal neurons and their modulation by NGF or serotonin. Mol. Pain 2 (2006) 11
47. Lindner A., et al. Meningeal hyperperfusion visualized by MRI in a patient with visual hallucinations and migraine. Headache 36 (1996) 53-57
48. Arnold G., et al. Migraine with aura shows gadolinium enhancement which is reversed following prophylactic treatment. Cephalalgia 18 (1998) 644-646
49. Knotkova H., and Pappagallo M. Imaging intracranial plasma extravasation in a migraine patient: a case report. Pain Med. 8 (2007) 383-387
50. Strassman A.M., et al. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384 (1996) 560-564
51. Burstein R., et al. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123 Pt 8 (2000) 1703-1709
52. Burstein R., and Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol. 55 (2004) 27-36
53. Levy D., et al. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4274-4279
54. Dray A., and Perkins M. Bradykinin and inflammatory pain. Trends Neurosci. 16 (1993) 99-104
55. Manning D.C., et al. Pain and hyperalgesia after intradermal injection of bradykinin in humans. Clin. Pharmacol. Ther. 50 (1991) 721-729
56. Ebersberger A., et al. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 89 (1999) 901-907
57. Kress M., et al. Calcitonin gene-related peptide and prostaglandin E2 but not substance P release induced by antidromic nerve stimulation from rat skin in vitro. Neuroscience 89 (1999) 303-310
58. Sarchielli P., et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J. Pain 8 (2007) 737-745
59. Lewin G.R., and Mendell L.M. Nerve growth factor and nociception. Trends Neurosci. 16 (1993) 353-359
60. Woolf C.J., et al. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62 (1994) 327-331
61. Lewin G.R., et al. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J. Neurosci. 13 (1993) 2136-2148
62. Petty B.G., et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann. Neurol. 36 (1994) 244-246
63. Burbach G.J., et al. The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J. Invest Dermatol. 117 (2001) 1075-1082
64. Dallos A., et al. Effects of the neuropeptides substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide and galanin on the production of nerve growth factor and inflammatory cytokines in cultured human keratinocytes. Neuropeptides 40 (2006) 251-263
65. Sarchielli P., et al. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 57 (2001) 132-134
66. Lopshire J.C., and Nicol G.D. The cAMP transduction cascade mediates the prostaglandin E2 enhancement of the capsaicin-elicited current in rat sensory neurons: whole-cell and single-channel studies. J. Neurosci. 18 (1998) 6081-6092
67. Smith J.A., et al. Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A. Eur. J. Neurosci. 12 (2000) 3250-3258
68. Gu Q., et al. Ca2+ transient evoked by chemical stimulation is enhanced by PGE2 in vagal sensory neurons: role of cAMP/PKA signaling pathway. J. Neurophysiol. 89 (2003) 1985-1993
69. Moriyama T., et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol. Pain 1 (2005) 3
70. Tominaga M., et al. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6951-6956
71. Cesare P., et al. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 23 (1999) 617-624
72. Premkumar L.S., and Ahern G.P. Induction of vanilloid receptor channel activity by protein kinase C. Nature 408 (2000) 985-990
73. Sugiura T., et al. Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J. Neurophysiol. 88 (2002) 544-548
74. Huang J., et al. Inflammatory pain: the cellular basis of heat hyperalgesia. Curr. Neuropharmacol. 4 (2006) 197-206
75. Numazaki M., et al. Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J. Biol. Chem. 277 (2002) 13375-13378
76. Chuang H.H., et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 411 (2001) 957-962
77. Shu X., and Mendell L.M. Nerve growth factor acutely sensitizes the response of adult rat sensory neurons to capsaicin. Neurosci. Lett. 274 (1999) 159-162
78. Bonnington J.K., and McNaughton P.A. Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J. Physiol. 551 (2003) 433-446
79. Prescott E.D., and Julius D. A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 300 (2003) 1284-1288
80. Zhuang Z.Y., et al. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J. Neurosci. 24 (2004) 8300-8309
81. Stein A.T., et al. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J. Gen. Physiol. 128 (2006) 509-522
82. Van Buren J.J., et al. Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol. Pain 1 (2005) 17
83. Zhang X., et al. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 24 (2005) 4211-4223
84. Morenilla-Palao C., et al. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J. Biol. Chem. 279 (2004) 25665-25672
85. Shah B.H., and Catt K.J. Calcium-independent activation of extracellularly regulated kinases 1 and 2 by angiotensin II in hepatic C9 cells: roles of protein kinase Cdelta, Src/proline-rich tyrosine kinase 2, and epidermal growth receptor trans-activation. Mol. Pharmacol. 61 (2002) 343-351
86. Amaya F., et al. Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain Res. 963 (2003) 190-196
87. Tohda C., et al. Axonal transport of VR1 capsaicin receptor mRNA in primary afferents and its participation in inflammation-induced increase in capsaicin sensitivity. J. Neurochem. 76 (2001) 1628-1635
88. Ji R.R., et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36 (2002) 57-68
89. Puntambekar P., et al. Essential role of Rac1/NADPH oxidase in nerve growth factor induction of TRPV1 expression. J. Neurochem. 95 (2005) 1689-1703
90. Bron R., et al. Activation of Ras is necessary and sufficient for upregulation of vanilloid receptor type 1 in sensory neurons by neurotrophic factors. Mol. Cell Neurosci. 22 (2003) 118-132
91. Schicho R., et al. Increased expression of TRPV1 receptor in dorsal root ganglia by acid insult of the rat gastric mucosa. Eur. J. Neurosci. 19 (2004) 1811-1818
92. Goadsby P.J. The pharmacology of headache. Prog. Neurobiol. 62 (2000) 509-525
93. Friberg L., et al. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 338 (1991) 13-17
94. Buzzi M.G., and Moskowitz M.A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol. 99 (1990) 202-206
95. Goadsby P.J., and Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33 (1993) 48-56
96. Goadsby P.J., and Edvinsson L. Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34 (1994) 394-399
97. Schoenen J., et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia 28 (2008) 1095-1105
98. Cady R., et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 27 (2007) 1055-1060
99. Welch K.M., et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 20 (2000) 687-695
100. Diamond S., et al. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 20 (2000) 597-602
101. Wong G.Y., and Gavva N.R. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res. Rev. 60 (2009) 267-277
102. Gavva N.R., et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136 (2008) 202-210
103. Chizh B.A., et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132 (2007) 132-141
104. Lambert G.A., et al. The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch. Pharmacol. 380 (2009) 311-325
105. Khasar S.G., et al. A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron 24 (1999) 253-260
106. Castrillo A., et al. Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection. J. Exp. Med. 194 (2001) 1231-1242
107. Campochiaro P.A. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol. Vis. Sci. 45 (2004) 922-931
108. McGill J.B., et al. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert. Opin. Drug Saf. 5 (2006) 835-845